Analysis and design of randomised clinical trials involving competing risks endpoints

Trials

Volumn 12, Issue , 2011, Pages

  Tai, Bee Choo ^a   Wee, Joseph ^b   Machin, David ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CHEMORADIOTHERAPY; DISTANT METASTASIS; EVENT FREE SURVIVAL; HAZARD ASSESSMENT; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LOG RANK TEST; NASOPHARYNX CANCER; PROCESS DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SAMPLE SIZE; BIOASSAY; DISEASE FREE SURVIVAL; METHODOLOGY; NASOPHARYNX TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS; TIME; TREATMENT FAILURE; TUMOR RECURRENCE;

DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, STATISTICAL; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; TIME FACTORS; TREATMENT FAILURE;

EID: 79955990271     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-127     Document Type: Article

References (28)

1. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JGF, Massie BM, Rydén L. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003, 89:42-48. 10.1136/heart.89.1.42, 1767481, 12482789.
2. Tai BC, Grundy R, Machin D. On the importance of accounting for competing risks in paediatric cancer trials designed to delay or avoid radiotherapy. I. Basic concepts and first analyses. Int J Radiat Oncol Biol Phys 2010, 76:1493-1499. 10.1016/j.ijrobp.2009.03.035, 19577860.
3. Tai BC, Grundy R, Machin D. On the importance of accounting for competing risks in paediatric brain cancer: II. Regression modelling and sample size. Int J Radiat Oncol Biol Phys 2011, 79:1139-1146. 10.1016/j.ijrobp.2009.12.024, 20472355.
4. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang ETL, Lee KM, Fong KW, Khoo Tan HS, Lee KS, Loong S, Sethi VJ, Chua EJ. Machin D Randomised phase III trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1977) Stage 3 and 4 nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005, 23:6730-6738. 10.1200/JCO.2005.16.790, 16170180.
5. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008, 26:4027-4034. 10.1200/JCO.2007.12.9866, 2654314, 18711194.
6. Tai BC, De Stavola BL, De Gruttola V, Gebski V, Machin D. First event or marginal estimation of cause-specific hazards for analysing correlated multivariate failure-time data?. Stat Med 2008, 27:922-936. 10.1002/sim.2944, 17551931.
7. Lee AWM, Poon YF, Foo W, Law SCK, Cheung FK, Chan DKK, Tung SY, Thaw M, Ho JHC. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976 - 1985. Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1987, 23:261-270.
8. Tai BC, Machin D, White I, Gebski V. Competing risks analysis of patients with osteosarcoma: A comparison of four different approaches. Stat Med 2001, 20:661-684. 10.1002/sim.711, 11241570.
9. Machin D, Cheung YB, Parmar MKB. Survival analysis a practical approach. 2006, Chichester: Wiley, 2.
10. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988, 16:1141-1154.
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
12. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2002, New Jersey: Wiley, 2.
13. Logan BR, Zhang MJ, Klein JP. Regression models for hazard rates versus cumulative incidence probabilities in hematopoietic cell transplantation data. Biol Blood Marrow Transplant 2006, 12:107-112.
14. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007, 13:559-565. 10.1158/1078-0432.CCR-06-1210, 17255278.
15. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983, 39:499-503. 10.2307/2531021, 6354290.
16. Latouche A, Porcher R, Chevret S. Sample size formula for proportional hazards modelling of competing risks. Stat Med 2004, 23:3263-3274. 10.1002/sim.1915, 15490425.
17. Pintilie M. Competing risks: A practical perspective. 2006, Chichester: Wiley.
18. Latouche A, Porcher R. Sample size calculations in the presence of competing risks. Stat Med 2007, 26:5370-5380. 10.1002/sim.3114, 17955563.
19. Machin D, Campbell MJ, Tan SB, Tan SH. Sample size tables for clinical studies. 2009, Chichester: Wiley-Blackwell, 3.
20. Schulgen G, Olschewski M, Krane V, Wanner C, Gunther R, Schumacher M. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials 2005, 26:386-396. 10.1016/j.cct.2005.01.010, 15911472.
21. Stata survival analysis and epidemiological tables reference manual release 11. 2009, College Station, TX: StataCorp LP.
22. Bajorunaite R, Klein JP. Comparison of failure probabilities in the presence of competing risks. J Stat Comput Sim 2008, 78:951-966.
23. Friedlin B, Korn EL. Testing treatment effects in the presence of competing risks. Stat Med 2005, 24:1703-1712. 10.1002/sim.2054, 15706579.
24. Williamson PR, Kolamunnage-Dona R, Smith CT. The influence of competing-risks setting on the choice of hypothesis test for treatment effect. Biostatistics 2007, 8:689-694.
25. Beyersmann J, Schumacher M. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med 2007, 26:5360-5369. (Letter).
26. Latouche A, Boisson V, Chevret S, Porcher R. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med 2007, 26:965-974.
27. Beyersmann J, Dettenkofer M, Bertz H, Schumacher R. A competing risks analysis of bloodstream infection after stem cell transplantation using subdistribution and cause-specific hazards. Stat Med 2007, 26:5360-5369.
28. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD, Brennan MF. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 1993, 88:400-409.